Sarah A. Weiss

3.6k total citations · 1 hit paper
66 papers, 2.0k citations indexed

About

Sarah A. Weiss is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Sarah A. Weiss has authored 66 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 21 papers in Molecular Biology and 16 papers in Immunology. Recurrent topics in Sarah A. Weiss's work include Cancer Immunotherapy and Biomarkers (27 papers), Immunotherapy and Immune Responses (15 papers) and CAR-T cell therapy research (13 papers). Sarah A. Weiss is often cited by papers focused on Cancer Immunotherapy and Biomarkers (27 papers), Immunotherapy and Immune Responses (15 papers) and CAR-T cell therapy research (13 papers). Sarah A. Weiss collaborates with scholars based in United States, Germany and United Kingdom. Sarah A. Weiss's co-authors include Mario Sznol, Harriet M. Kluger, Jedd D. Wolchok, Iman Osman, Ana Luisa Perdigoto, Kevan C. Herold, Scott Gettinger, James Lee, Zoe Quandt and Arabella Young and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Sarah A. Weiss

61 papers receiving 2.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

2018 412 citations Ana Luisa Perdigoto, Harriet M. Kluger et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sarah A. Weiss United States	21	1.2k	512	477	405	219	66	2.0k
Paul Maddison United Kingdom	32	427 0.4×	729 1.4×	288 0.6×	346 0.9×	271 1.2×	81	3.1k
Galia Tsarfaty Israel	23	557 0.5×	497 1.0×	437 0.9×	206 0.5×	83 0.4×	60	1.7k
Sreenivasa R Chandana United States	17	694 0.6×	350 0.7×	129 0.3×	264 0.7×	191 0.9×	86	1.4k
Hong In Yoon South Korea	21	809 0.7×	239 0.5×	252 0.5×	587 1.4×	202 0.9×	133	2.0k
Jasmine H. Francis United States	32	829 0.7×	827 1.6×	286 0.6×	622 1.5×	312 1.4×	191	3.6k
Rahul Jandial United States	25	881 0.7×	1.0k 2.0×	207 0.4×	529 1.3×	167 0.8×	99	2.8k
Yasmeen Sarfraz United States	9	969 0.8×	526 1.0×	904 1.9×	336 0.8×	73 0.3×	13	1.8k
Deborah S. Barkauskas United States	17	815 0.7×	552 1.1×	771 1.6×	191 0.5×	86 0.4×	34	1.9k
Allen Waziri United States	28	581 0.5×	512 1.0×	578 1.2×	278 0.7×	233 1.1×	51	2.2k
Adı́lia Hormigo United States	23	1.0k 0.9×	725 1.4×	215 0.5×	467 1.2×	113 0.5×	56	2.6k

Countries citing papers authored by Sarah A. Weiss

Since Specialization

Citations

This map shows the geographic impact of Sarah A. Weiss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah A. Weiss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah A. Weiss more than expected).

Fields of papers citing papers by Sarah A. Weiss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah A. Weiss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah A. Weiss. The network helps show where Sarah A. Weiss may publish in the future.

Co-authorship network of co-authors of Sarah A. Weiss

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah A. Weiss. A scholar is included among the top collaborators of Sarah A. Weiss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah A. Weiss. Sarah A. Weiss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Palmeri, Marisa, Sarah A. Weiss, & Phillip R. Purnell. (2025). Case Report: Recurrent supraglottitis in a patient with metastatic melanoma treated with ipilimumab and nivolumab. Frontiers in Oncology. 15. 1615835–1615835. 1 indexed citations

Mahajan, Amit, Sarah A. Weiss, Thuy Tran, et al.. (2024). Patterns of brain metastases response to immunotherapy with pembrolizumab. Journal of Neuro-Oncology. 169(3). 555–561. 3 indexed citations

Su, David, Jeffrey J. Ishizuka, Thuy Tran, et al.. (2024). Real-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma. 2(1). 100120–100120.

Greene, Spencer, et al.. (2023). Anticonvulsant fatalities reported to the American Association of Poison Control Centers 2000 - 2019. Seizure. 106. 1–6. 3 indexed citations

Krykbaeva, Irina, William Damsky, Meaghan K. McGeary, et al.. (2023). Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance. Cancer Immunology Research. 11(10). 1332–1350. 12 indexed citations

Weiss, Sarah A., Ulrich‐Wilhelm Thomale, Matthias Schulz, et al.. (2023). Neurosurgical morbidity in pediatric supratentorial midline low‐grade glioma: Results from the German LGG studies. International Journal of Cancer. 153(8). 1487–1500. 4 indexed citations

Davar, Diwakar, Alexandra P. Ikeguchi, Elizabeth I. Buchbinder, et al.. (2023). A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).. Journal of Clinical Oncology. 41(16_suppl). TPS9594–TPS9594. 4 indexed citations

Miller, Brian C., Rose Al Abosy, Jenna L. Collier, et al.. (2023). Abstract 6362: Overcoming resistance to immunotherapy due to loss of antigen presentation. Cancer Research. 83(7_Supplement). 6362–6362.

Weiss, Sarah A., Mario Sznol, Montaser Shaheen, et al.. (2023). A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy. Clinical Cancer Research. 30(1). 74–81. 28 indexed citations

10.

Heng, Jacob S., Kathleen Stoessel, Sarah A. Weiss, et al.. (2022). Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review. BMJ Open Ophthalmology. 7(1). e000889–e000889. 16 indexed citations

11.

Jessel, Shlomit, Sarah A. Weiss, Matthew Austin, et al.. (2022). Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. Frontiers in Oncology. 12. 836859–836859. 47 indexed citations

12.

Esposito, Andrew C., Daniel Jacobs, Stephan Ariyan, et al.. (2021). Merkel Cell Carcinoma: Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally. Annals of Surgical Oncology. 29(1). 415–424. 3 indexed citations

13.

Klemen, Nicholas D., Melinda Wang, Jill C. Rubinstein, et al.. (2020). Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. Journal for ImmunoTherapy of Cancer. 8(1). e000341–e000341. 63 indexed citations

14.

Hu, Jamie K., William Damsky, Kelly Olino, et al.. (2020). Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series. JAAD Case Reports. 6(7). 628–633. 10 indexed citations

15.

Gao, Catherine A., Urs M. Weber, Aldo J. Peixoto, & Sarah A. Weiss. (2019). Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma. Journal for ImmunoTherapy of Cancer. 7(1). 262–262. 17 indexed citations

16.

Jilaveanu, Lucia B., Mäneka Puligandla, Sarah A. Weiss, et al.. (2017). Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805. Clinical Cancer Research. 24(1). 217–223. 24 indexed citations

17.

Varela, Carmen, Sarah A. Weiss, Michael M. Halassa, et al.. (2016). Tracking the Time-Dependent Role of the Hippocampus in Memory Recall Using DREADDs. PLoS ONE. 11(5). e0154374–e0154374. 18 indexed citations

18.

Zhong, Judy, Joon Lee, Sarah A. Weiss, et al.. (2016). Melanoma brain metastases: correlation of imaging features with genomic markers and patient survival. Journal of Neuro-Oncology. 131(2). 341–348. 14 indexed citations

19.

Guo, Jennifer N., Robert Kim, Yu Chen, et al.. (2016). Impaired consciousness in patients with absence seizures investigated by functional MRI, EEG, and behavioural measures: a cross-sectional study. The Lancet Neurology. 15(13). 1336–1345. 71 indexed citations

20.

Chang, Gregory, Yongzhao Shao, Yilong Zhang, et al.. (2015). Sensitivity of plasma BRAF^mutant and NRAS^mutant cell‐free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non‐RECIST disease progression. Molecular Oncology. 10(1). 157–165. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact